[1] T.F. Greten, Treatment of liver cancer, Liver Biol. Pathobiol. (2020) 782–791.
https://doi.org/10.1002/9781119436812.ch61.
[2] S.P. Metkar, G. Fernandes, P.D. Navti, A.N. Nikam, R. Kudarha, N. Dhas, R.N. Seetharam, K.V. Santhosh, B.S.S. Rao, S. Mutalik, Nanoparticle drug delivery systems in hepatocellular carcinoma: A focus on targeting strategies and therapeutic applications, OpenNano. 12 (2023) 100159.
https://doi.org/10.1016/j.onano.2023.100159.
[3] M. Yazdani, M. Rahmandoust, H. Kouchakzadeh, Development of various carbon nanoparticles and albumin complexes for potential theranostics applications, J. Drug Deliv. Sci. Technol. 77 (2022) 103901.
https://doi.org/10.1016/j.jddst.2022.103901.
[4] R.A. Revia, M. Zhang, Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: Recent advances, Mater. Today. 19 (2016) 157–168.
https://doi.org/10.1016/j.mattod.2015.08.022.
[5] S. Raeispour, M. Rahmandoust, H. Kouchakzadeh, A nanocarrier system based on CQDs for efficient mitoxantrone drug delivery, Heliyon. 10 (2024) e31674.
https://doi.org/10.1016/j.heliyon.2024.e31674.
[6] S. Lorente, M. Hautefeuille, A. Sanchez-Cedillo, The liver, a functionalized vascular structure, Sci. Rep. 10 (2020) 1–10.
https://doi.org/10.1038/s41598-020-73208-8.
[7] A.K. Burroughs, The Hepatic Artery, Portal Venous System and Portal Hypertension: The Hepatic Veins and Liver in Circulatory Failure, Sherlock’s Dis. Liver Biliary Syst. 12th Ed. (2011) 152–209.
[8] N.M. Tunissiolli, M.M.U. Castanhole-Nunes, P.M. Biselli-Chicote, É.C. Pavarino, R.F. da Silva, R. de C.M.A. da Silva, E.M. Goloni-Bertollo, Hepatocellular carcinoma: A comprehensive review of biomarkers, clinical aspects, and therapy, Asian Pacific J. Cancer Prev. 18 (2017) 863–872.
https://doi.org/10.22034/APJCP.2017.18.4.863.
[9] I. Lurje, Z. Czigany, J. Bednarsch, C. Roderburg, P. Isfort, U.P. Neumann, G. Lurje, Treatment strategies for hepatocellular carcinoma—A multidisciplinary approach, Int. J. Mol. Sci. 20 (2019) 1–27.
https://doi.org/10.3390/ijms20061465.
[10] J. Yu, Z.Z. Wu, T. Li, Y. Xu, Y.C. Zhao, B.L. Zhang, T. Li, Y.C. Zhao, H. Tian, Effectiveness of surgical resection for complicated liver cancer and its influencing factors: A retrospective study, World J. Clin. Cases. 8 (2020) 736–742.
https://doi.org/10.12998/wjcc.v8.i4.736.
[11] Y.K. Cho, J.K. Kim, M.Y. Kim, H. Rhim, J.K. Han, Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies, Hepatology. 49 (2009) 453–459.
https://doi.org/10.1002/hep.22648.
[12] M. Ikeda, C. Morizane, M. Ueno, T. Okusaka, H. Ishii, J. Furuse, Chemotherapy for hepatocellular carcinoma: Current status and future perspectives, Jpn. J. Clin. Oncol. 48 (2018) 103–114.
https://doi.org/10.1093/jjco/hyx180.
[13] C.P. Chen, Role of radiotherapy in the treatment of hepatocellular carcinoma, J. Clin. Transl. Hepatol. 7 (2019) 183–190.
https://doi.org/10.14218/JCTH.2018.00060.
[14] N. Mahmoudi, F. Fatemi, M. Rahmandoust, F. Mirzajani, S.O. Ranaei Siadat, Development of a carbon quantum dot-based sensor for the detection of acetylcholinesterase and the organophosphate pesticide, Heliyon. 9 (2023) e19551.
https://doi.org/10.1016/j.heliyon.2023.e19551.
[15] M. Mohammadian, H. Kouchakzadeh, M. Rahmandoust, T. Mohammadian, Targeted albumin nanoparticles for the enhancement of gemcitabine toxicity on cancerous cells, J. Drug Deliv. Sci. Technol. 56 (2020) 101503.
https://doi.org/10.1016/j.jddst.2020.101503.
[16] K. Mahmoud, S. Swidan, M. El-Nabarawi, M. Teaima, Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances, J. Nanobiotechnology. 20 (2022) 1–42.
https://doi.org/10.1186/s12951-022-01309-9.
[17] L. Qi, Z. Xu, M. Chen, In vitro and in vivo suppression of hepatocellular carcinoma growth by chitosan nanoparticles, Eur. J. Cancer. 43 (2007) 184–193.
https://doi.org/10.1016/j.ejca.2006.08.029.
[18] P. Pandey, M. Rahman, P.C. Bhatt, S. Al, B. Paul, A. Hafeez, F.A. Al-Abbasi, M.S. Nadeem, O. Baothman, F. Anwar, V. Kumar, Implication of nano-antioxidant therapy for treatment of hepatocellular carcinoma using PLGA nanoparticles of rutin, Nanomedicine. 13 (2018) 849–870.
https://doi.org/10.2217/nnm-2017-0306.
[19] M. Zhou, Y. Yi, L. Liu, Y. Lin, J. Li, J. Ruan, Z. Zhong, Polymeric micelles loading with ursolic acid enhancing anti-tumor effect on hepatocellular carcinoma, J. Cancer. 10 (2019) 5820–5831.
https://doi.org/10.7150/jca.30865.
[20] S. Kianamiri, A. Dinari, M. Sadeghizadeh, M. Rezaei, B. Daraei, N.E.H. Bahsoun, A. Nomani, Mitochondria-Targeted Polyamidoamine Dendrimer-Curcumin for Hepatocellular Cancer Treatment, Mol. Pharm. 17 (2020) 4483–4498.
https://doi.org/10.1021/acs.molpharmaceut.0c00566.
[21] Y. Li, S. Wang, Z. Wang, X. Qian, J. Fan, X. Zeng, Y. Sun, P. Song, M. Feng, D. Ju, Cationic poly(amidoamine) dendrimers induced cyto-protective autophagy in hepatocellular carcinoma cells, Nanotechnology. 25 (2014) 455101.
https://doi.org/10.1088/0957-4484/25/45/455101.
[22] E. Ahmadian, S.M. Dizaj, E. Rahimpour, A. Hasanzadeh, A. Eftekhari, H. Hosainzadegan, J. Halajzadeh, H. Ahmadian, Effect of silver nanoparticles in the induction of apoptosis on human hepatocellular carcinoma (HepG2) cell line, Mater. Sci. Eng. C. 93 (2018) 465–471.
https://doi.org/10.1016/j.msec.2018.08.027.
[23] A. Jędrzak, B.F. Grześkowiak, K. Golba, E. Coy, K. Synoradzki, S. Jurga, T. Jesionowski, R. Mrówczyński, Magnetite nanoparticles and spheres for chemo- and photothermal therapy of hepatocellular carcinoma in vitro, Int. J. Nanomedicine. 15 (2020) 7923–7936.
https://doi.org/10.2147/IJN.S257142.
[24] A. Saei, S. Asfia, H. Kouchakzadeh, M. Rahmandoust, Antibody-modified magnetic nanoparticles as specific high-efficient cell-separation agents, J. Biomed. Mater. Res. - Part B Appl. Biomater. 108 (2020) 2633–2642.
https://doi.org/10.1002/jbm.b.34595.
[25] G. Tom, S. Philip, R. Isaac, P.K. Praseetha, S.G. Jiji, V.V. Asha, Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma, Life Sci. 206 (2018) 10–21. https://. 93 (2018) 465–471.
https://doi.org/10.1016/j.msec.2018.08.027.
[23] A. Jędrzak, B.F. Grześkowiak, K. Golba, E. Coy, K. Synoradzki, S. Jurga, T. Jesionowski, R. Mrówczyński, Magnetite nanoparticles and spheres for chemo- and photothermal therapy of hepatocellular carcinoma in vitro, Int. J. Nanomedicine. 15 (2020) 7923–7936.
https://doi.org/10.2147/IJN.S257142.
[24] A. Saei, S. Asfia, H. Kouchakzadeh, M. Rahmandoust, Antibody-modified magnetic nanoparticles as specific high-efficient cell-separation agents, J. Biomed. Mater. Res. - Part B Appl. Biomater. 108 (2020) 2633–2642.
https://doi.org/10.1002/jbm.b.34595.
[25] G. Tom, S. Philip, R. Isaac, P.K. Praseetha, S.G. Jiji, V.V. Asha, Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma, Life Sci. 206 (2018) 10–21.
https://doi.org/10.1016/j.lfs.2018.04.046.
[26] H. Koulivand, A. Shahbazi, V. Vatanpour, M. Rahmandoost, Novel antifouling and antibacterial polyethersulfone membrane prepared by embedding nitrogen1186/s12951-022-01275-2.
[30] M. Rahmandoust, A. Öchsner, On finite element modeling of single- and multi-walled carbon nanotubes, J. Nanosci. Med. 11 (2021).
https://doi.org/10.3390/jpm11080771.
[31] M.M.A. Elsayed, M.E. Mostafa, E. Alaaeldin, H.A.A. Sarhan, M.S. Shaykoon, S. Allam, A.R.H. Ahmed, Design and Optimization of Pectinate-Coated Niosomes for Enhancing the Oral Bioavailability of Methotrexate: In Vitro and In Vivo Evaluation, Pharmaceutics. 14 (2022) 2223.
https://doi.org/10.3390/pharmaceutics14102223.
[32] S. Taghizadeh, V. Alimardani, P.L. Roudbali, Y. Ghasemi, E. Kaviani, Gold nanoparticles as a promising candidate for hepatocellular carcinoma therapy: A review, J. Drug Deliv. Sci. Technol. 64 (2021) 102606.
https://doi.org/10.1016/j.jddst.2021.102606.
[33] M.F. Attia, N. Anton, J. Wallyn, Z. Omran, T.F. Vandamme, An overview of active and passive targeting strategies to improve the delivery of various drugs to treat hepatocellular carcinoma, J. Control. Release. 226 (2016) 193–204.
https://doi.org/10.1016/j.jconrel.2016.02.030.
[34] S. Dhar, F.X. Gu, R. Langer, O.C. Farokhzad, S.J. Lippard, Targeted delivery of cisplatin to prostate cancer cells by dual-targeting Pt(IV) nanoparticles, Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 17356–17361.
https://doi.org/10.1073/pnas.0809154105.
[35] Y. Guang, Ligand-modified Nanomaterials for Specific Targeting of Hepatocellular Carcinoma, J. Mod. Nanotechnol. 2 (2022) 1–8.
https://doi.org/10.53964/jmn.2022004.
[36] N. Kadeh, S. Sen, A. McClain, J.E. Puskas, J.A. Drazba, G. McLennan, Folic acid conjugated polymeric drug delivery vehicle for targeted cancer detection in hepatocellular carcinoma, J. Biomed. Mater. Res. - Part A. 107 (2019) 2522–2535.
https://doi.org/10.1002/jbm.a.36758.
[37] Y. Xu, M. Wang, S. Ning, Z. Yang, L. Zhou, X. Xia, Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma, Molecules. 27 (2022) 6786.
https://doi.org/10.3390/molecules27206786.
[38] A. Bakrania, G. Zheng, M. Bhat, Nanomedicine in hepatocellular carcinoma: A new frontier in targeted cancer treatment, Pharmaceutics. 14 (2022) 1–25.
https://doi.org/10.3390/pharmaceutics14010041.
[39] K. Golla, B. Cherukuvada, F. Ahmed, A.K. Kondapi, Efficacy, Safety and Anticancer Activity of Protein Nanoparticle-Based Delivery of Doxorubicin through Intravenous Administration in Rats, PLoS One. 7 (2012) e51960.
https://doi.org/10.1371/journal.pone.0051960.
[40] V. Kumar, M. Rahman, P. Gahtori, F. Al-Abbasi, F. Anwar, H.S. Kim, Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine, Expert Opin. Drug Deliv. 18 (2021) 673–694.
https://doi.org/10.1080/17425247.2021.1860939.
[41] F.H. Kong, Q.F. Ye, X.Y. Miao, X. Liu, S.Q. Huang, L. Xiong, Y. Wen, Z.J. Zhang, Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma, Theranostics. 11 (2021) 5464–5490.
https://doi.org/10.7150/thno.54822.
[42] Q. Zhou, L. Zhang, T.H. Yang, H. Wu, Stimuli-responsive polymeric micelles for drug delivery and cancer therapy, Int. J. Nanomedicine. 13 (2018) 2921–2942.
https://doi.org/10.2147/IJN.S158696.
[43] P.W. Lee, C.T. Chen, H.W. Sung, M.C. Chen, Paclitaxel-loaded poly(γ-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system against cultured HepG2 cells, Bioconjug. Chem. 17 (2006) 291–299.
https://doi.org/10.1021/bc0502107.
[44] C. Zhang, T. An, D. Wang, G. Wan, M. Zhang, H. Wang, S. Zhang, R. Li, X. Yang, Y. Wang, Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma, J. Control. Release. 226 (2016) 193–204.
https://doi.org/10.1016/j.jconrel.2016.02.030.
[45] D. Ling, H. Xia, W. Park, M.J. Hackett, C. Song, K. Na, K.M. Hui, T. Hyeon, PH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma, ACS Nano. 8 (2014) 8027–8039.
https://doi.org/10.1021/nn502074x.
[46] C. Niu, Q. Sun, J. Zhou, D. Cheng, G. Hong, Folate-functionalized polymeric micelles based on biodegradable PEG-PDLLA as a hepatic carcinoma-targeting delivery system, Asian Pacific J. Cancer Prev. 12 (2011) 1995–1999.
[47] G.L. Malarvizhi, A.P. Retnakumari, S. Nair, M. Koyakutty, Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma, Nanomedicine Nanotechnology, Biol. Med. 10 (2014) 1649–1659.
https://doi.org/10.1016/j.nano.2014.05.011.
[48] W. Zhang, F. Peng, T. Zhou, Y. Huang, L. Zhang, P. Ye, M. Lu, G. Yang, Y. Gai, T. Yang, X. Ma, G. Xiang, Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes, Int. J. Nanomedicine. 10 (2015) 4825–4836.
https://doi.org/10.2147/IJN.S79598.
